S'abonner

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study - 04/11/20

Doi : 10.1016/S1470-2045(20)30496-4 
Jianming Xu, ProfMD a, , , Lin Shen, ProfMD b, , Zhiwei Zhou, ProfMD c, Jie Li, ProfMD b, Chunmei Bai, ProfMD d, Yihebali Chi, ProfMD e, Zhiping Li, ProfMD f, Nong Xu, ProfMD g, Enxiao Li, ProfMD h, Tianshu Liu, ProfMD i, Yuxian Bai, ProfMD j, Ying Yuan, ProfMD k, Xingya Li, ProfMD l, Xiuwen Wang, ProfMD m, Jia Chen, ProfMD n, Jieer Ying, ProfMD o, Xianjun Yu, ProfMD p, Shukui Qin, ProfMD q, Xianglin Yuan, ProfMD r, Tao Zhang, ProfMD s, Yanhong Deng, ProfMD t, Dianrong Xiu, ProfMD u, Ying Cheng, ProfMD v, Min Tao, ProfMD w, Ru Jia, MD a, Wei Wang, MD c, Jing Li, MD x, Songhua Fan, MD x, Mengye Peng, PhD x, Weiguo Su, PhD x
a Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China 
b Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China 
c Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China 
d Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China 
e National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 
f Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China 
g Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China 
h Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China 
i Department of Medical Oncology, Zhongshan Hospital of Fudan University, Shanghai, China 
j Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China 
k Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China 
l Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China 
m Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, China 
n Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China 
o Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, China 
p Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai, China 
q People’s Liberation Army Cancer Center of Nanjing Jinling Hospital, Nanjing, China 
r Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 
s Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 
t Department of Medical Oncology, The Sixth Affiliated Hospital, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases l, Sun Yat-sen University, Guangzhou, Guangdong, China 
u Department of General Surgery, Peking University Third Hospital, Beijing, China 
v Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun, China 
w Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China 
x Department of Clinical Development and Regulatory Affairs, Hutchison MediPharma, Shanghai, China 

* Correspondence to: Dr Jianming Xu, Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China Department of Gastrointestinal Oncology The Fifth Medical Center Chinese PLA General Hospital Beijing 100071 China

Summary

Background

Therapeutic options for advanced neuroendocrine tumours (NETs) are limited. We investigated the efficacy and safety of surufatinib (HMPL-012, sulfatinib) in patients with extrapancreatic NETs.

Methods

SANET-ep was a randomised, double-blind, placebo-controlled, phase 3 trial undertaken at 24 hospitals across China. Patients (aged 18 years or older) with unresectable or metastatic, well differentiated, extrapancreatic NETs, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and progression on no more than two types of previous systemic regimens were enrolled. Patients were centrally randomly assigned (2:1) using stratified block randomisation (block size 3) via an interactive web response system to receive oral surufatinib at 300 mg per day or matching placebo. Randomisation was stratified by tumour origin, pathological grade, and previous treatment. Patients, investigators, research staff and the sponsor study team were masked to treatment allocation. Crossover to the surufatinib group was allowed for patients in the placebo group at disease progression. The primary endpoint was investigator-assessed progression-free survival, which was analysed in the intention-to-treat population. A preplanned interim analysis was done at 70% of predicted progression-free survival events. This study was registered with ClinicalTrials.gov, NCT02588170. Follow-up is ongoing.

Findings

Between Dec 9, 2015, and March 31, 2019, 198 patients were randomly assigned to surufatinib (n=129) or placebo (n=69). Median follow-up was 13·8 months (95% CI 11·1–16·7) in the surufatinib group and 16·6 months (9·2–not calculable) in the placebo group. Investigator-assessed median progression-free survival was 9·2 months (95% CI 7·4–11·1) in the surufatinib group versus 3·8 months (3·7–5·7) in the placebo group (hazard ratio 0·33; 95% CI 0·22–0·50; p<0·0001). As the trial met the predefined criteria for early discontinuation of the study at the interim analysis, the study was terminated early, as recommended by the independent data monitoring committee. The most common treatment-related adverse events of grade 3 or worse were hypertension (47 [36%] of 129 patients in the surufatinib group vs nine [13%] of 68 patients in the placebo group) and proteinuria (25 [19%] vs zero). Treatment-related serious adverse events were reported in 32 (25%) of 129 patients in the surufatinib group and nine (13%) of 68 patients in the placebo group. Treatment-related deaths occurred in three patients in the surufatinib group (disseminated intravascular coagulation and hepatic encephalopathy, liver injury, and death with unknown reason) and one patient in the placebo group (cachexia and respiratory failure).

Interpretation

Progression-free survival was significantly longer in patients given surufatinib compared with patients given placebo, and surufatinib has a favourable benefit-to-risk profile in patients with progressive, advanced, well differentiated extrapancreatic NETs. Our results suggest that surufatinib might be a new treatment option for this population.

Funding

Hutchison MediPharma.

Le texte complet de cet article est disponible en PDF.

Plan


© 2020  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 21 - N° 11

P. 1500-1512 - novembre 2020 Retour au numéro
Article précédent Article précédent
  • Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
  • Jianming Xu, Lin Shen, Chunmei Bai, Wei Wang, Jie Li, Xianjun Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihebali Chi, Yongmei Yin, Wenhui Lou, Nong Xu, Yuxian Bai, Tao Zhang, Dianrong Xiu, Xiuwen Wang, Ying Yuan, Jia Chen, Shukui Qin, Ru Jia, Ming Lu, Yuejuan Cheng, Zhiwei Zhou, Jing Li, James He, Weiguo Su
| Article suivant Article suivant
  • Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
  • Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, Cora N Sternberg, Johann de Bono, Daniel Castellano, Bertrand Tombal, Christian Wülfing, Michael Liontos, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Theodore, Susan Feyerabend, Carole Helissey, Stéphane Oudard, Gaetano Facchini, Elizabeth M Poole, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Samira Bensfia, Ronald de Wit

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.